The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Biomarker-driven prediction of ibrutinib response in Waldenström macroglobulinemia
Tina Bagratuni, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses whether genomic, proteogenomic and circulating tumor cell (CTC)-based approaches could become routine pre-treatment testing to predict ibrutinib response in Waldenström’s macroglobulinemia over the next five to ten years. She highlights the potential to identify a small number of readily accessible biomarkers that could be incorporated into routine laboratory testing and help clinicians select treatment based on the biological profile of each patient. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, I think in the next five to ten years these tools are going to be much more available and much more easily accessible in different clinical practices or centers for routine analysis because at the time now we have very advanced technologies and very advanced informatics, but we will end up with just a few features that are genes or plasma proteomics or CTCs or the transcriptome profiles. So we will end up with a few features that can be easily accessible, easily run on every laboratory...
Yes, I think in the next five to ten years these tools are going to be much more available and much more easily accessible in different clinical practices or centers for routine analysis because at the time now we have very advanced technologies and very advanced informatics, but we will end up with just a few features that are genes or plasma proteomics or CTCs or the transcriptome profiles. So we will end up with a few features that can be easily accessible, easily run on every laboratory. And then we can be much more precise on how clinicians will select their patients based on the biological profile of WM patients and just not go with a random therapy which is not very precise to each patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
